The Brazilian company Uniao Quimica, which has an agreement with RDIF for the production of Sputnik V, has requested the right to conduct clinical trials of the drug from the Anvisa National Sanitary Inspection Agency.
According to RIA Novosti, the request will be analyzed within three days.
It is noted that Anvisa’s permission is a prerequisite for research, the result of which will be the registration of the drug in the future.
Recall that in October, the Russian Direct Investment Fund (RDIF), Uniao Quimica Farmaceutica Nacional and the government of the Brazilian state of Parana submitted a set of documents to the country’s National Sanitary Inspection Agency for registration of the Russian Sputnik V vaccine.
The production of the first batches of the Russian vaccine on the territory of the republic was planned for the near future.